Patents Assigned to Conversion Energy Enterprises, Inc.
  • Publication number: 20160250377
    Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 1, 2016
    Applicant: CONVERSION ENERGY ENTERPRISES, INC.
    Inventors: Barbara A. Soltz, Robert Soltz
  • Patent number: 9012406
    Abstract: Disclosed herein are compositions comprising gelatin, collagen, and a chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation. These compositions have also been found to be strong tissue adhesives that crosslinks the composition and tissue and are effective in closing and sealing wounds, fixation of grafts/implants and anastomoses.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 21, 2015
    Assignee: Conversion Energy Enterprises, Inc.
    Inventors: Barbara A. Soltz, Robert Soltz
  • Patent number: 9006182
    Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 14, 2015
    Assignee: Conversion Energy Enterprises, Inc.
    Inventors: Barbara A. Soltz, Robert Soltz